BTG3 and interstitial lung disease: Although there is no consensus on the optimal serologic tests for initial ILD evaluation, recent guidelines recommend ANA, anticyclic citrullinated peptide, and rheumatoid factor testing in all patients with suspected ILD, even in the absence of CTD features; and the ENA antibodies panel is advised when clinical suspicion is high, based on clinical findings or a positive ANA result [3,12].